×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ £¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

±í¹ÛÒÅ´«ÐÞÊÎ £¬ÈçDNA¼×»ù»¯ £¬ÔÚÒÅ´«ÐÅÏ¢µÄ±í´ïÖÐʩչ×ÅÖ÷Òª×÷Óá£DNA¼×»ù×ªÒÆÃ¸Î¬³ÖDNA¼×»ù»¯ £¬ÊÇÖ×Áö»¯ÁƵÄÒ»¸öÓÐÎüÒýÁ¦µÄ°Ðµã

2023-07-06
|
»á¼ûÁ¿£º

Epigenetic modification, like DNA methylation, plays a major role in the expression of genetic information. The DNA methyltransferases (DNMTs), maintain DNA methylation, is an attractive target for tumor chemotherapy. WK-23 displays a good inhibitory effect on human DNMT1 with an IC50 value of 5.0??M. The PK profile of WK-23 was obtained with quite satisfying oral bioavailability and elimination half-life. In vivo pharmacokinetic properties of WK-22, WK-23, WK-27, and DC_517 were performed by Medicilon.

35.jpg

Reference:

Ennian Li, et al. Design, synthesis, and biological evaluation of novel carbazole derivatives as potent DNMT1 inhibitors with reasonable PK properties. J Enzyme Inhib Med Chem. 2022 Dec;37(1):1537-1555. doi: 10.1080/14756366.2022.2079640.

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿